AKT1 and neoplasm: As anticipated, ER+ BC tumour PDX models CTC174 and T272 with activating mutations in PI3KCA alone were responsive to both inhibition of AKT (capivasertib) and PI3Kα (alpelisib) (Fig. 3B).